Nanomedicine for improvement of dendritic cell-based cancer immunotherapy
| Autor: | Mohammad Hojjat-Farsangi, Brinton Seashore-Ludlow, Vida Hashemi, Farhad Jadidi-Niaragh, Mitra Ghasemi Chaleshtari, Hamed Mohammadi, Afshin Namdar, Ghasem Ghalamfarsa, Ali Masjedi, Shohreh Farhadi, Amir Ajjoolabady |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_treatment Immunology Lymphocyte Activation Cancer Vaccines Immunotherapy Adoptive 03 medical and health sciences Delivery methods Drug Delivery Systems 0302 clinical medicine Immune system Cancer immunotherapy Neoplasms medicine Animals Humans Immunology and Allergy Pharmacology Antigen delivery business.industry Cancer Dendritic Cells Dendritic cell medicine.disease Nanomedicine 030104 developmental biology Targeted drug delivery 030220 oncology & carcinogenesis Cancer research Nanoparticles business |
| Zdroj: | International Immunopharmacology. 83:106446 |
| ISSN: | 1567-5769 |
| DOI: | 10.1016/j.intimp.2020.106446 |
| Popis: | Dendritic cell (DC)-based cancer immunotherapy has shown impressive outcomes, including the development of the first FDA-approved anti-cancer vaccine. However, the clinical application of DC-based cancer immunotherapy is associated with various challenges. Promising novel tools for the administration of cancer vaccines has emerged from recent developments in nanoscale biomaterials. One current strategy to enhance targeted drug delivery, while minimizing drug-related toxicities, is the use of nanoparticles (NPs). These can be utilized for antigen delivery into DCs, which have been shown to provide potent T cell-stimulating effects. Therefore, NP delivery represents one promising approach for creating an effective and stable immune response without toxic side effects. The current review surveys cancer immunotherapy with particular attention toward NP-based delivery methods that target DCs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect